BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SNY upcoming catalysts
Sanofi: 13 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (5 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 37 readout(s) and 1 FDA event(s). Subscribe to SNY (.ics).
Drugs: Itepekimab, Amlitelimab, Yellow fever vaccine, Mometasone furoate, Dupilumab, rilzabrutinib, PCV21, brivekimig, SAR441566, Measles, combinations, mumps, rubella, live attenuated, Pandemic flu H5 HA mRNA SD2 vaccine, SAR442970, frexalimab, Investigational hMPV/RSV vaccine, Investigational hMPV vaccine, Investigational RSV vaccine, Licensed RSV Vaccine, Investigational RSV, hMPV vaccine, SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab, Isatuximab, Carfilzomib, Dexamethasone, Methylprednisolone, Atezolizumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-25 est. | P3 | Sanofi SNY | NCT07216079 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Immune Thrombocytopenia | active not recruiting | 3 |
| 2026-11-28 est. | P3 | Sanofi SNY | NCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Yellow Fever Immunization | active not recruiting | 2440 |
| 2026-12-01 est. | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06838000 Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, a | Pneumococcal Infections | active not recruiting | 1268 |
| 2026-12-01 est. | P1/P2 | Sanofi SNY | NCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain | Pandemic Influenza Immunization; Healthy Volunteers | active not recruiting | 720 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease | Crohn's Disease | recruiting | 99 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 105 |
| 2026-12-23 est. | P2 | Sanofi SNY | NCT06500702 A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomeru | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | recruiting | 84 |
| 2027-01-07 est. | P3 | Sanofi SNY | NCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sickle Cell Disease | recruiting | 100 |
| 2027-01-18 est. | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Yea | Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization | active not recruiting | 1530 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
| 2027-02-09 est. | P2 | Sanofi SNY | NCT07170917 Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | recruiting | 208 |
| 2027-02-11 est. | P2 | Sanofi SNY | NCT06984627 A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | Graves' Disease | recruiting | 30 |
| 2027-02-17 est. | P3 | Sanofi SNY | NCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 59 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-07-09 | FDA approval | approved | SANOFI-AVENTIS U.S. LLC SNY | SARCLISA ESCENA | Approved 2026-07-09: SARCLISA ESCENA (BLA761445 ORIG1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-29 | P2 | Sanofi SNY | NCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-L | Colitis Ulcerative; Crohn's Disease | terminated | 7 |
| 2026-09-24 | P3 | Sanofi SNY | NCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 216 |
| 2026-09-23 | P3 | Sanofi SNY | NCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusi | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 231 |
| 2026-09-22 | P2 | Sanofi SNY | NCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Prev | Asthma | terminated | 335 |
| 2026-09-10 | P3 | Sanofi SNY | NCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Chronic Obstructive Pulmonary Disease | completed | 669 |
| 2026-09-04 | P2 | Sanofi SNY | NCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 109 |
| 2026-08-06 | P2 | Sanofi SNY | NCT06867094 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | Colitis Ulcerative | terminated | 170 |
| 2026-08-05 | P2 | Sanofi SNY | NCT06557772 A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease | Coeliac Disease; Celiac Disease | active not recruiting | 229 |
| 2026-07-30 | P2 | Sanofi SNY | NCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | Crohn's Disease | terminated | 105 |
| 2026-06-10 | P3 | Sanofi SNY | NCT06407934 A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 1 | Dermatitis Atopic | active not recruiting | 1541 |
| 2026-06-10 | P3 | Sanofi SNY | NCT06290128 A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do | Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinatin | active not recruiting | 109 |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687980 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 138 |
| 2026-06-08 | P3 | Sanofi SNY | NCT06687967 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged | Lichen Simplex Chronicus | completed | 142 |
| 2026-05-22 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06744205 A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older | Influenza; Healthy Volunteers | completed | 1162 |
| 2026-05-22 | P3 | Sanofi SNY | NCT05280548 A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease | Fabry Disease | active not recruiting | 104 |
| 2026-05-13 | P2 | Sanofi SNY | NCT05731128 A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulce | Colitis Ulcerative | active not recruiting | 68 |
| 2026-05-01 | P3 | Sanofi SNY | NCT07135986 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China | Meningococcal Infection; Healthy Volunteers | completed | 1602 |
| 2026-04-16 | P1/P2 | Sanofi SNY | NCT06695117 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inact | COVID-19 Immunization; Influenza Immunization | completed | 980 |
| 2026-04-03 | P1/P2 | Sanofi SNY | NCT06695130 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Inf | COVID-19 Immunization; Influenza Immunization | completed | 980 |
| 2026-03-31 | P2 | Sanofi SNY | NCT06691113 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nas | Chronic Rhinosinusitis Without Nasal Polyps | completed | 66 |
| 2026-03-24 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06727058 Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | Influenza Immunization | completed | 276 |
| 2026-03-02 | P3 | Sanofi SNY | NCT06805513 Actual Use Trial of Tadalafil 5 mg | Erectile Dysfunction | completed | 2212 |
| 2026-03-02 | P3 | Sanofi SNY | NCT04910776 Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa | Glycogen Storage Disease Type II | active not recruiting | 17 |
| 2026-02-27 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06134648 Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate | Respiratory Syncytial Virus Infection; Healthy Volunteers; Human Metapneumovirus | completed | 646 |
| 2026-02-23 | P2 | Sanofi SNY | NCT06102005 Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma | Asthma | completed | 685 |
| 2026-02-12 | P2 | Sanofi SNY | NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic | Dermatitis Atopic | completed | 150 |
| 2026-02-10 | P2 | Sanofi SNY | NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | Colitis Ulcerative | active not recruiting | 187 |
| 2026-01-29 | P2 | Sanofi SNY | NCT06454240 A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 79 |
| 2026-01-20 | P3 | Sanofi SNY | NCT07002060 Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults | Yellow Fever Immunization | completed | 640 |
| 2026-01-12 | P3 | Sanofi SNY | NCT07079670 Safety and Immunogenicity of NVX-CoV2705 | COVID-19; SARS-CoV-2 Infection | completed | 676 |
| 2025-12-26 | P3 | Sanofi SNY | NCT03485677 Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 | Gaucher's Disease Type I; Gaucher's Disease Type III | completed | 57 |
| 2025-12-25 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT07222059 Phase 3 Single Arm, Open Study on vYF in Adults | Yellow Fever | completed | 254 |
| 2025-12-22 | P2 | Sanofi SNY | NCT05704049 A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple | Relapsed/Refractory Multiple Myeloma | active not recruiting | 118 |
| 2025-12-22 | P1/P2 | Sanofi SNY | NCT05450562 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Neoplasm | terminated | 33 |
| 2025-12-17 | P3 | Sanofi SNY | NCT05206773 A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease | Fabry Disease | active not recruiting | 122 |
| 2025-12-04 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06252285 Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | RSV Immunisation | terminated | 6300 |
| 2025-11-25 | P3 | Sanofi SNY | NCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate- | Dermatitis Atopic | completed | 589 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.